Genovis AB (publ.) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was SEK 102.39 million compared to SEK 93.02 million a year ago. Net income was SEK 11.19 million compared to SEK 24.78 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
33.75 SEK | -2.17% | +12.13% | -35.10% |
May. 15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.10% | 211M | |
-4.47% | 12.33B | |
-4.35% | 8.14B | |
+30.65% | 5.62B | |
-8.09% | 4.24B | |
-54.43% | 3.06B | |
+14.44% | 2.76B | |
-1.49% | 2.41B | |
+31.19% | 2.23B | |
-4.67% | 1.87B |
- Stock Market
- Equities
- GENO Stock
- News Genovis AB
- Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2022